Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis ...( SAN DIEGO Oct. 30 /- Anadys Pharm...)

SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it has initiated dosing ANA773 in patients chronically infected with hepatitis C virus (HCV) in Part B of a two-part protocol designed to test ANA773 in both healthy volunteers and HCV patients. ANA773 is the Company's investigational oral TLR7 agonist prodrug. In Part B of the study, patients in the first cohort will receive 800 mg of ANA773 every other day for 28 days. Doses for subsequent cohorts will be selected based on viral load and tolerability data from the 800 mg cohort.

"The initiation of patient dosing in this study of ANA773 marks the second study that Anadys has initiated in HCV patients this quarter, having commenced patient dosing earlier this week with ANA598, our non-nucleoside polymerase inhibitor," said Steve Worland, Ph.D., President and CEO of Anadys. "With two independent and potentially complementary HCV programs advancing toward viral load data, we look forward to demonstrating the breadth of our portfolio in this important therapeutic area."

ANA773 Phase I Study in HCV - Part B

In Part B of the study, patients in the first cohort will receive 800 mg of ANA773 every other day for 28 days. Doses for subsequent cohorts will be selected based on viral load and tolerability data from the 800 mg cohort. Anadys expects to have viral load data from the 800 mg cohort in the first quarter of 2009 and a complete data set in the second quarter of 2009.

About ANA773 and TLR Pharmacology

In July, Anadys announced that it was resuming clinical investigation of the TLR7 mechanism in HCV by taking ANA773 into a clinical trial under a two-part protocol designed to test ANA773 in both heal
'/>"/>